文献速递心律失常

经皮磁刺激治疗室性心动过速风暴的随机临床试验

Effect of Transcutaneous Magnetic Stimulation in Patients With Ventricular Tachycardia Storm: A Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2022-01-01

这项双盲假刺激对照随机试验在单中心纳入26例24小时内发作≥3次室速的成人患者,比较单次靶向左星状神经节的经皮磁刺激与假刺激。主要终点24小时无室速发作两组差异无统计学意义,但72小时室速发作频率显著降低,且未发现对心脏植入电子装置功能的显著影响。

要点

  • 24小时无室速发作率TcMS组29% vs 假刺激组58%,差异无统计学意义。
  • 72小时室速发作均值TcMS组4.5次 vs 假刺激组10.7次,发生率比0.42。
  • 7例携带心脏植入电子装置者未出现临床显著的装置功能影响。

核心结论

  • 在本随机临床试验中,结果支持经皮磁刺激可安全降低室速风暴患者的室速负荷。

研究设计与样本

  • 双盲、假刺激对照随机临床试验,2019年8月至2021年7月在单中心进行。
  • 纳入26例成人患者,24小时内室速发作≥3次。
  • 随机接受单次靶向左星状神经节的经皮磁刺激(n=14)或假刺激(n=12)。

主要发现

  • TcMS组7例携带心脏植入电子装置的患者均未出现临床显著的装置功能影响。

临床怎么用

  • 对于室速风暴患者,单次经皮磁刺激左星状神经节可能作为辅助治疗以减少短期室速负荷。
  • 携带心脏植入电子装置的患者接受经皮磁刺激未观察到临床显著的装置功能影响。

局限性

  • 单中心、样本量小(26例),主要终点24小时无室速发作未达统计学显著。
  • 单次刺激 session,随访时间短,长期疗效与安全性未评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Autonomic neuromodulation provides therapeutic benefit in ventricular tachycardia (VT) storm. Transcutaneous magnetic stimulation (TcMS) can noninvasively and nondestructively modulate a patient's nervous system activity and may reduce VT burden in patients with VT storm. OBJECTIVE: To evaluate the safety and efficacy of TcMS of the left stellate ganglion for patients with VT storm. DESIGN, SETTING, AND PARTICIPANTS: This double-blind, sham-controlled randomized clinical trial took place at a single tertiary referral center between August 2019 and July 2021. The study included 26 adult patients with 3 or more episodes of VT in 24 hours. INTERVENTIONS: Patients were randomly assigned to receive a single session of either TcMS that targeted the left stellate ganglion (n = 14) or sham stimulation (n = 12). MAIN OUTCOMES AND MEASURES: The primary outcome was freedom from VT in the 24-hour period following randomization. Key secondary outcomes included safety of TcMS on cardiac implantable electronic devices, as well as burden of VT in the 72-hour period following randomization. RESULTS: Among 26 patients (mean [SD] age, 64 [13] years; 20 [77%] male), a mean (SD) of 12.7 (10.3) episodes of VT occurred within the 24 hours preceding randomization. Patients had recurrent VT despite taking a mean (SD) of 2.0 (0.6) antiarrhythmic drugs (AADs), and 11 patients (42%) required mechanical hemodynamic support at the time of randomization. In the 24-hour period after randomization, VT recurred in 4 of 14 patients (29% [SD 47%]) in the TcMS group vs 7 of 12 patients (58% [SD 51%]) in the sham group (P = .20). In the 72-hour period after randomization, patients in the TcMS group had a mean (SD) of 4.5 (7.2) episodes of VT vs 10.7 (13.8) in the sham group (incidence rate ratio, 0.42; P < .001). Patients in the TcMS group were taking fewer AADs 24 hours after randomization compared with baseline (mean [SD], 0.9 [0.8] vs 1.8 [0.4]; P = .001), whereas there was no difference in the number of AADs taken for the sham group (mean [SD], 2.3 [0.8] vs 1.9 [0.5]; P = .20). None of the 7 patients in the TcMS group with a cardiac implantable electronic device had clinically significant effects on device function. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, findings support the potential for TcMS to safely reduce the burden of VT in the setting of VT storm in patients with and without cardiac implantable electronic devices and inform the design of future trials to further investigate this novel treatment approach. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04043312.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Markman TM, Pothineni NVK, Zghaib T, et al. Effect of Transcutaneous Magnetic Stimulation in Patients With Ventricular Tachycardia Storm: A Randomized Clinical Trial. JAMA Cardiol. 2022. PMID: 35171197. doi:10.1001/jamacardio.2021.6000

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。